Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Short-term Investments (2016 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Short-term Investments for 9 consecutive years, with $436.0 million as the latest value for Q4 2024.

  • On a quarterly basis, Short-term Investments rose 19.9% to $436.0 million in Q4 2024 year-over-year; TTM through Dec 2024 was $436.0 million, a 19.9% increase, with the full-year FY2024 number at $436.0 million, up 19.9% from a year prior.
  • Short-term Investments was $436.0 million for Q4 2024 at Ultragenyx Pharmaceutical, up from $283.1 million in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $614.8 million in Q4 2022 to a low of $283.1 million in Q2 2024.
  • A 5-year average of $456.1 million and a median of $440.2 million in 2022 define the central range for Short-term Investments.
  • Peak YoY movement for Short-term Investments: surged 59.31% in 2021, then tumbled 40.86% in 2023.
  • Ultragenyx Pharmaceutical's Short-term Investments stood at $488.0 million in 2020, then decreased by 11.35% to $432.6 million in 2021, then soared by 42.12% to $614.8 million in 2022, then tumbled by 40.86% to $363.6 million in 2023, then rose by 19.9% to $436.0 million in 2024.
  • Per Business Quant, the three most recent readings for RARE's Short-term Investments are $436.0 million (Q4 2024), $283.1 million (Q2 2024), and $363.6 million (Q4 2023).